<
https://www.theguardian.com/society/2026/may/31/daily-pill-daraxonrasib-double-survival-time-pancreatic-pancreas-cancer-clinical-trial>
"A daily pill can double survival time in patients with the world’s deadliest
cancer, according to the results of a clinical trial that experts are saying is
a “gamechanger” and one of the biggest breakthroughs in decades.
Currently, there are few treatments for pancreatic cancer, and most do little
or nothing to help. For decades, scientists have worked relentlessly trying to
find clever solutions for a form of cancer that is often found late. More than
half of patients are only diagnosed after it has spread.
Now experts at the world’s largest cancer conference are hailing the arrival of
a smart drug called daraxonrasib, which they say could pave the way for a
treatment revolution.
In the trial of 500 patients, all of whom had pancreatic cancer that had
spread, the pill doubled survival time, with fewer side-effects compared with
chemotherapy. The findings were presented at the American Society of Clinical
Oncology’s (Asco) annual meeting in Chicago.
Patients who took the drug lived substantially longer, for an average of 13.2
months, compared with 6.6 to 6.7 months for patients who had chemotherapy, the
trial found.
“These results are landscape-changing,” said Dr Rachna Shroff, the chief of
oncology at the University of Arizona Cancer Center and an Asco expert in
gastrointestinal cancers, who was not involved with the study. “We are seeing
unprecedented survival.”
When Shroff first read the results of the trial, led by researchers at the
world-renowned Dana-Farber Cancer Institute in Boston, she wept, she said.
“Having treated pancreatic cancer for 16 years, I actually started crying in
clinic. This is such an incredibly impactful study for our patients, and I
really congratulate the [trial] investigators.”"
Cheers,
*** Xanni ***
--
mailto:xanni@xanadu.net Andrew Pam
http://xanadu.com.au/ Chief Scientist, Xanadu
https://glasswings.com.au/ Partner, Glass Wings
https://sericyb.com.au/ Manager, Serious Cybernetics
